Skip to main content

Table 1 Analysis of variance on the three selected groups​​

From: Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin

 

Not admitted (n = 158; 11.0%)

Admitted without event (n = 986; 68.7%)

Admitted with event (n = 292; 20.3%)

P

Age (years)

51.6 ± 12.8

62.5 ± 15.3*

71.3 ± 12#°

 < 0.001

Male gender

82 (51.9%)

617 (62.6%)*

206 (70.6)#°

 < 0.001

Creatinine (mg/dl)

0.80 [0.69–0.94]

0.96 [0.78–1.16]*

1.16 [0.87–1.62]#°

 < 0.001

Platelets (/mmc)

233.99 ± 127.70

232.03 ± 96.86

210.23 ± 94.21#°

0.003

MR-proADM (nmol/L)

0.57 [0.48–0.71]

0.83 [0.63–1.16]*

1.33 [0.97–2.03]#°

 < 0.001

WBC (/mmc)

5.40 [4.35–6.50]

6.44 [4.72–8.70]*

7.53 [5.28–10.88]#°

 < 0.001

Lymphocytes (/mmc)

1.20 [0.80–1.61]

0.98 [0.70–1.33]*

0.57 [0.81–1.14]#°

 < 0.001

LDH (U/L)

471 [392–599]

389 [276–555]*

510 [375–735]#°

 < 0.001

PCT (mg/dl)

0.05 [0.03–0.08]

0.08 [0.04–0.14]*

0.18 [0.09–0.46]#°

 < 0.001

CRP (mg/L)

19.65 [9.42–46.12]

60.07 [25–106.59]*

103.12 [55.67–176]#°

 < 0.001

Cardiovascular disease

8 (5.1%)

216 (21.9%) *

102 (34.9%)#°

 < 0.001

Chronic respiratory diseases

9 (5.7%)

148 (15.0%)*

65 (22.3%)#°

 < 0.001

Diabetes

17 (10.8%)

175 (17.8%)

111 (38%)#°

 < 0.001

Chronic kidney disease

2 (1.3%)

100 (10.1%)*

83 (28.4%)#°

 < 0.001

Malignancy

6 (3.8%)

61 (6.2%)

28 (9.6%)

0.039

Hypertension

28 (17.7%)

455 (46.2%)*

184 (63%)#°

 < 0.001

  1. *: p < 0.05 post-hoc “not admitted” vs “admitted without event”; #: p < 0.05 post-hoc “not admitted” vs “admitted with event”; °: p < 0.05 post-hoc “admitted without event” vs “admitted with event”